25 January 2016
Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis
A new study published on the Journal of Cancer Research and Therapy focuses on the relationship between COPD and lung cancer.
The aim of this study is to develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria in a single-institution cohort of patients with newly diagnosed lung cancer.
Primary objective was investigating the effects of impaired lung function with various histological cell types on crude survival, while considering the initial staging of disease extent.
The study results confirm that the presence and severity of COPD in lung cancer patients is an independent predictor of survival time, different from the established staging of initial extent of disease.
The study is available free to download at the following link: click here
Founded in 1980, COSMED is a privately owned company manufacturing Cardio Pulmonary and Metabolic Diagnostic Equipment. COSMED products include a full range of Spirometers, Pulmonary Function, Body Composition, Nutritional Assessment and Cardio Pulmonary Exercise systems, including Electrocardiographs, Ergometers and Assessment Software. COSMED solutions are aimed for either professional or medical use for many different applications like: Hospital, Clinics, Primary Care, University & Education in Human Physiology, Clinical Nutrition, Commercial Weight Management, Human Performance Centers, Sport Institutions and Health Club Industry. COSMED Headquarters are located in the province of Rome, Italy. COSMED has subsidiaries in the USA, China and Germany, and distributes its products internationally through a constantly growing distributor network covering more than 70 countries.